▼ -7.79% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for MyoKardia in the last 3 months. The average price target is $207.40, with a high forecast of $225.00 and a low forecast of $86.00. The average price target represents a -7.79% upside from the last price of $224.91.
The current consensus among 11 polled investment analysts is to hold stock in MyoKardia. This Hold consensus rating has held steady for over two years.
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.